ISL
RDHL

Ingalls & Snyder LLC’s Redhill Biopharma RDHL Stock Holding History

Ingalls & Snyder LLC’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29
Closed -$133K – 480
2021
Q3 		$133K Buy
29
+10
+53% +$67.8K 0.01% 446
2021
Q2 		$131K Hold
19
– – 0.01% 446
2021
Q1 		$143K Hold
19
– – 0.01% 422
2020
Q4 		$157K Sell
19
-1
-5% -$8.99K 0.01% 407
2020
Q3 		$202K Sell
20
-1
-5% -$8.2K 0.01% 343
2020
Q2 		$141K Buy
21
+1
+5% +$6.89K 0.01% 383
2020
Q1 		$89K Hold
20
– – 0.01% 390
2019
Q4 		$119K Buy
+20
New +$128K 0.01% 386
2019
Q2 		– Sell
-12
Closed -$101K – 434
2019
Q1 		$101K Hold
12
– – ﹤0.01% 402
2018
Q4 		$68K Sell
12
-1
-8% -$7.66K ﹤0.01% 399
2018
Q3 		$116K Sell
13
-1
-7% -$8.15K ﹤0.01% 429
2018
Q2 		$117K Hold
14
– – 0.01% 392
2018
Q1 		$71K Buy
14
+3
+27% +$17.3K ﹤0.01% 388
2017
Q4 		$55K Sell
11
-30
-73% -$202K ﹤0.01% 388
2017
Q3 		$446K Sell
41
-1
-2% -$8.89K 0.02% 253
2017
Q2 		$358K Hold
42
– – 0.02% 274
2017
Q1 		$398K Hold
42
– – 0.02% 279
2016
Q4 		$435K Hold
42
– – 0.02% 265
2016
Q3 		$577K Hold
42
– – 0.03% 237
2016
Q2 		$451K Buy
+42
New +$486K 0.03% 268

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Ingalls & Snyder LLC's RDHL Position: Q4 2021 in Review

Ingalls & Snyder LLC sold out of Redhill Biopharma (RDHL) in Q4 2021, closing a stake of 29 shares — an estimated $133K sold.

Ingalls & Snyder LLC first reported a position in RDHL in Q2 2016 and held it in 20 quarters. The position peaked at $577K in Q3 2016. 51 funds tracked by Wall St. Rank hold RDHL as of Q4 2021.

  • Ingalls & Snyder LLC reported no remaining Redhill Biopharma position as of Q4 2021 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 29 Redhill Biopharma shares in Q4 2021, an estimated $133K.
  • Ingalls & Snyder LLC first reported a position in Redhill Biopharma in Q2 2016 and held it in 20 quarters.
  • Ingalls & Snyder LLC's Redhill Biopharma position peaked at $577K in Q3 2016.
  • 51 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2021.

Based on Ingalls & Snyder LLC's 13F filing for Q4 2021, filed 11 Feb 2022.